Effects of chronic desipramine treatment on α2-adrenoceptors and μ-opioid receptors in the guinea pig cortex and hippocampus

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 116-125

  Giaroni, Cristina ^a   Canciani, Luca ^a   Zanetti, Elena ^a   Giuliani, Daniela ^a   Pisani, Rossana ^a   Oldrini, Rita ^a   Moro, Elisabetta ^a   Trinchera, Marco ^a   Crema, Francesca ^a   Lecchini, Sergio ^a   Frigo, Gianmario ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

2 adrenoceptor; opioid receptor; (Guinea pig); Chronic desipramine treatment; Cortex; Hippocampus

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; DESIPRAMINE; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 2; G PROTEIN COUPLED RECEPTOR KINASE 3; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; GUINEA PIG; HIPPOCAMPUS; IMMUNOBLOTTING; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYNAPTOSOME;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CEREBRAL CORTEX; DESIPRAMINE; G-PROTEIN-COUPLED RECEPTOR KINASE 2; G-PROTEIN-COUPLED RECEPTOR KINASE 3; GENE EXPRESSION REGULATION; GTP-BINDING PROTEIN ALPHA SUBUNITS; GUINEA PIGS; HIPPOCAMPUS; MALE; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, OPIOID, MU; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNAPTOSOMES;

EID: 37549044323     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.007     Document Type: Article

References (71)

1. Ammer H., and Schulz R. Retinoic acid-induced differentiation of human neuroblastoma SH-SY5Y cells is associated with changes in the abundance of G-proteins. J. Neurochem. 62 (1994) 1310-1318
2. Avissar S., and Schreiber G. The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clin. Chim. Acta 366 (2006) 37-47
3. 2-adrenoceptors in the rat brain. Mol. Pharmacol. 42 (1992) 846-855
4. 3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine. J. Pharm. Pharmacol. 41 (1989) 865-867
5. Bevilacqua A., Ceriani M.C., Capaccioli S., and Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J. Cell. Physiol. 195 (2003) 356-372
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
7. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum. Psychopharmacol. Clin. Exp. 19 (2004) S21-S25
8. 2-adrenoceptors, μ- and κ-opioid receptors in the guinea pig myenteric plexus: effect of chronic desipramine treatment. Eur. J. Pharmacol. 553 (2006) 269-279
9. Chalberg S.C., Duda T., Rhine J.A., and Sharma R.K. Molecular cloning, sequencing and expression of an α2-adrenergic receptor complementary DNA from rat brain. Mol. Cell. Biochem. 97 (1990) 161-172
10. Chen J., and Rasenick M.N. Chronic treatment of C6 glioma cells with antidepressant drugs increases functional coupling between a G protein (Gs) and adenylyl cyclase. J. Neurochem. 64 (1995) 724-732
11. Chen F., and Lawrence A.J. Chronic antidepressant treatment causes a selective reduction of μ-opioid receptor binding and functional coupling to G proteins in the amygdala of fawn-hooded rats. J. Pharmacol. Exp. Ther. 310 (2004) 1020-1026
12. Clinton S.M., Sucharski I.L., and Finlay J.M. Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex. Psychopharmacology 183 (2006) 404-412
13. Connor M., and Christie M.J. Opioid receptor signalling mechanisms. Clin. Exp. Pharmacol. Physiol. 26 (1999) 493-499
14. De Felipe M.C., De Ceballos M.L., Gil C., and Fuentes J.A. Chronic antidepressant treatment increases enkephalin levels in N. accumbens and striatum of the rat. Eur. J. Pharmacol. 112 (1985) 119-122
15. De Paermentier F., Mauger J.M., Lowther S., Crompton M.R., Katona C.L.E., and Horton R.W. Brain α-adrenoceptors in depressed suicides. Brain Res. 757 (1997) 60-68
16. Díaz A., Pazos A., Flórez J., Ayesta F.J., Santana V., and Hurlé M.A. Regulation of μ-opioid receptors, G-protein-coupled receptor kinases and β-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience 112 (2002) 345-353
17. Donati R.J., and Rasenick M.M. G protein signaling and the molecular basis of antidepressant action. Life Sci. 73 (2003) 1-17
18. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord. 4 (2002) 183-194
19. Duman R.S., Malberg J., and Thome J. Neural plasticity to stress and antidepressant treatment. Biol. Psychiatry 46 (1999) 1181-1191
20. Duman R.S., Malberg J., Nagakawa S., and D'Sa C. Neuronal plasticity and survival in mood disorders. Biol. Psychiatry 48 (2000) 732-739
21. Dwivedi Y., and Pandey G.N. Effects of subchronic administration of antidepressants and anxiolytics on levels of the α subunits of G proteins in the rat brain. J. Neural Transm. 104 (1997) 747-760
22. Emamghoreishi M., Warsh J.J., Sibony D., and Li P.P. Lack of effect of chronic antidepressant treatment on Gs and Giα-subunit protein and mRNA levels in the rat cerebral cortex. Neuropsychopharmacology 15 (1996) 281-287
23. Ertley R.N., Bazinet R.P., Lee H.J., Rapoport S.I., and Rao J.S. Chronic treatment with mood stabilizers increases membrane GRK3 in rat frontal cortex. Biol. Psychiatry 61 (2007) 246-249
24. 1A-autoreceptors regulating monoamine synthesis in the rat brain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (1999) 135-143
25. Fuder H., and Muscholl E. Heteroreceptor-mediated modulation of noradrenaline and acetylcholine release from peripheral nerves. Rev. Physiol., Biochem. Pharmacol. 126 (1995) 265-412
26. Furst S. Transmitters involved in antinociception in the spinal cord. Brain Res. Bull. 48 (1999) 129-141
27. i2 subunit and down-regulation by antidepressant drug treatment. Biol. Psychiatry 42 (1997) 704-712
28. 2A-adrenoceptors, Gi coupling proteins and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem. 72 (1999) 282-291
29. 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology 29 (2004) 580-588
30. Gray E.G., and Whittaker V.P. The isolation of nerve endings from brain: an electron-microscopic study of cell fragments derived by homogenization and centrifugation. J. Anat. 96 (1962) 79-88
31. Gray A.M., Spencer P.S.J., and Sewell R.D.E. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds. Br. J. Pharmacol. 124 (1998) 669-674
32. Hamon M., Gozlan H., Bourgoin S., Benoliel J.J., Mauborgne A., Taquet H., Cesselin F., and Mico J.A. Opioid receptors and neuropeptides in the CNS in rats treated chronically with amoxapine or amitriptyline. Neuropharmacology 26 (1987) 531-539
33. 2-adrenoceptor desensitization by desipramine and ECS. Br. J. Pharmacol. 103 (1991) 1865-1870
34. Hu H.Y., Davis J.M., Heinze W.J., and Pandey G.N. Effect of chronic treatment with antidepressants on β-adrenergic receptor binding in guinea pig brain. Biochem. Pharmacol. 29 (1980) 2895-2896
35. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 (2004) 819-827
36. Isenberg K.E., and Cicero T.J. Possible involvement of opiate receptors in the pharmacological profiles of antidepressant compounds. Eur. J. Pharmacol. 103 (1984) 57-63
37. 2A-adrenergic receptors. Mol. Pharmacol. 64 (2003) 1317-1324
38. 2 adrenergic receptor agonists. Pain 87 (2000) 181-191
39. 2-adrenoceptor mediated autoinhibition of transmitter release from sympathetic varicosities of the mouse vas deferens. Br. J. Pharmacol. 132 (2001) 403-410
40. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
41. Landabaso M.A., Iraurgi I., Jiménez-Lerma J.M., Sanz J., Fernández de Corres B., Araluce K., Calle R., and Gutiérrez-Fraile M. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction 93 (1998) 739-744
42. Langer S.Z. 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol. Sci. 18 (1997) 95-99
43. Lesch K.P., and Manji H.K. Signal-transducing G proteins and antidepressant drugs: evidence for modulation of α subunit gene expression in rat brain. Biol. Psychiatry 32 (1992) 549-579
44. oα subunits. Eur. J. Pharmacol. 207 (1991) 361-364
45. 2-adrenoceptor, opioid κ-receptor and adenosine A1-receptor interactions on noradrenaline release in rabbit brain cortex. Naunyn-Schmiedeberg's Arch. Pharmacol. 338 (1988) 53-61
46. Magalas Z., De Vry J., and Tzschentke T.M. The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. Eur. J. Pharmacol. 528 (2005) 103-109
47. Maldonado R. Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci. Biobehav. Rev. 21 (1997) 91-104
48. Manier D.H., Bieck P.R., Duhl D.M., Gillespie D.D., and Sulser F. The β-adrenoceptor-coupled adenylate cyclase system in rat C6 glioma cells. Deamplification by isoproterenol and oxaprotiline. Neuropsychopharmacology 7 (1992) 105-112
49. 2-adrenoceptors regulating noradrenergic transmission in the rat brain: a dual-probe microdialysis study. Br. J. Pharmacol. 133 (2001) 1362-1370
50. Matsumoto M., Yoshioka M., Togashi H., Hirokami M., Tochihara M., Ikeda T., Smith C.B., and Saito H. μ-Opioid receptors modulate noradrenaline release from the rat hippocampus as measured by brain microdialysis. Brain Res. 636 (1994) 1-8
51. Miralles A., Asensio V.J., and García-Sevilla J.A. Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 43 (2002) 1249-1257
52. Newmann M.E., and Lerer B. Post-receptor-mediated increases in adenylate cyclase activity after chronic antidepressant treatment: relationship to receptor desensitization. Eur. J. Pharmacol. 162 (1989) 345-352
53. Ossipov M.H., Lopez Y., Bian D., Nichols M.L., and Porreca F. Synergistic antinociceptive interactions of morphine and clonidine in rats with nerve-ligation injury. Anesthesiology 86 (1997) 192-204
54. Pandey G.N., Heinze W.J., Brown B.D., and Davis J.M. Electroconvulsive shock treatment decrease β-adrenergic receptor sensitivity in rat brain. Nature 280 (1979) 234-235
55. Pitcher J.A., Freedman N.J., and Lefkowitz R.J. G protein-coupled receptor kinases. Ann. Rev. Biochem. 67 (1998) 653-692
56. Reisine T., and Soubrie P. Loss of rat cerebral cortical opiate receptors following chronic desipramine treatment. Eur. J. Pharmacol. 77 (1982) 39-44
57. 2-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 363 (2001) 66-72
58. Sacerdote P., Brini A., Mantegazza P., and Panerai A.E. A role for serotonin and β-endorphin in the analgesia induced by some tricyclic antidepressant drugs. Pharmacol. Biochem. Behav. 26 (1987) 153-158
59. Sarai K., Frazer A., Brunswick D., and Mendels J. Desmethylimipramine-induced decrease in β-adrenergic receptor binding in rat cerebral cortex. Biochem. Pharmacol. 27 (1978) 2179-2181
60. 2-adrenoceptors regulating monoamine synthesis in the brain of morphine-dependent rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 365 (2002) 210-219
61. Sawynok J., Esser M.J., and Reid A.R. Antidepressants as analgesics: an overview of central and peripheral mechanisms of action. J. Psychiatry Neurosci. 26 (2001) 21-29
62. 2-adrenoceptors attenuates the inhibitory effect of μ-opioid receptor agonists on noradrenaline release from brain slices. Naunyn-Schmiedeberg's Arch. Pharmacol. 333 (1986) 377-380
63. 2A-adrenergic receptor plays a protective role in mouse behavioural models of depression and anxiety. J. Neurosci. 21 (2001) 4875-4882
64. 1A receptor downregulation by antidepressants in rat brain. Neurochem. Int. 38 (2001) 573-579
65. Stengaard-Pedersen K., and Schou M. Opioid peptides and receptors in relation to affective illness. Effects of desipramine and lithium on opioid receptors in rat brain. Acta Pharmacol. Toxicol. 56 S1 (1985) 170-179
66. Subhash M.N., Nagaraja M.R., Sharada S., and Vinod K.Y. Cortical α-adrenoceptor downregulation by tricyclic antidepressants in the rat brain. Neurochem. Int. 43 (2003) 603-609
67. Sugrue M.F. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol. Ther. 21 (1983) 1-33
68. Taylor D.A., Leedham J.A., Doak N., and Fleming W.W. Morphine tolerance and nonspecific subsensitivity of the longitudinal muscle myenteric plexus preparation of the guinea pig to inhibitory agonists. Naunyn-Schmiedeberg's Arch. Pharmacol. 338 (1988) 553-559
69. Vilpoux C., Carpentier C., Leroux-Nicollet I., Naudon L., and Costentin J. Differential effects of chronic antidepressant treatments on μ- and δ-opioid receptors in rat brain. Eur. J. Pharmacol. 443 (2002) 85-93
70. Wahlstrom A., Lenhammar L., Ask B., and Rane A. Tricyclic antidepressants inhibit opioid receptor binding in human brain and hepatic morphine glucoronidation. Pharmacol. Toxicol. 75 (1994) 23-27
71. Wong D.T., Reid L.R., Bymaster F.P., and Threlkeld P.G. Chronic effects of fluoxetine, a selective inhibitor of serotonin uptake, on neurotransmitter receptors. J. Neural Transm. 64 (1985) 251-269